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Abstract
The effects of ultramicronized palmitoylethanolamide were evaluated on pain behaviours and markers of mast cell (MC) activity in
a rat model of endometriosis plus ureteral calculosis (ENDO1STONE)–induced viscerovisceral hyperalgesia (VVH). Female
Sprague-Dawley rats that underwent surgical induction of endometriosis were randomly assigned to receive active (ultramicronized
palmitoylethanolamide 10mg·kg21·d21, orally) or placebo treatment for 25 days. At day 21, they underwent ureteral stone formation
and were video-recorded till day 25 to evaluate ureteral and uterine pain behaviours. At autopsy (day 25), ureteral condition and
number and diameter of endometrial cysts were evaluated. The following were then measured: number and percentage of
degranulating MCs, number of vessels, chymase, nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and Flk-1
(VEGF receptor) in cysts, and NGF in dorsal root ganglia (DRG). Ultramicronized palmitoylethanolamide–treated vs placebo-treated
rats showed significantly lower number, duration and complexity of ureteral crises, shorter duration of uterine pain, and smaller cyst
diameter (0.0001 , P , 0.004); a significantly higher percentage of expelled stones (P , 0.0001); significantly lower MC number
(P, 0.01), vessel number (P, 0.01), chymase (P, 0.05), NGF (P, 0.05), VEGF (P, 0.01), and Flk-1 (P, 0.01) expression in cysts
and NGF expression in DRG (P, 0.01). In all animals, the global duration of ureteral crises correlated linearly and directly with cyst
diameter, MC number and chymase in cysts, and NGF in cysts and DRG (0.02 , P , 0.0002). Ultramicronized
palmitoylethanolamide significantly reduces VVH from ENDO1STONE, probably by modulating MC expression/activity in cysts,
thus reducing central sensitization due to noxious signals from endometriotic lesions. The results suggest potential utility of the
compound for VVH in clinics.
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1. Introduction
Endometriosis (ENDO) affects over 10% of women in their
reproductive years, causing sub/infertility and, frequently, pelvic
pain. Deep infiltrating endometriosis is the most painful form,
while ovarian ENDO cysts are generally poorly symptom-
atic.6,22,29,33,34,38,60,64,67 Even when asymptomatic for pain from
the reproductive organs, however, endometriosis can enhance
pain from other pelvic viscera with partially overlapping sensory
innervation. Women with “silent endometriosis” plus ureteral
calculosis (ENDO1STONE), in fact, show enhanced urinary pain,
a phenomenon known as viscerovisceral hyperalgesia (VVH),
where noxious inputs from the endometriotic lesions probably
sensitize neurons also receiving sensory input from the urinary
tract, thus facilitating the triggering of urinary pain.27,28 Our group
set up a rat model of VVH from silent endometriosis plus artificial
ureteral calculosis, where the rats show enhanced visceral pain
behaviour.26,44 Preventive ketoprofen treatment of ENDO lesions
(secretory cysts) in this model reduces cyst diameter and
prevents post-stone VVH, which confirms that reducing
nociceptive inputs from the cysts is key to preventing/
decreasing pain in this condition.26 Endometriosis treatment
with nonsteroidal anti-inflammatory drugs in humans, however,
remains problematic because clinically significant results would
require repeated/prolonged administration, something that is
not exempt from side effects.23,70 An imperative need therefore
exists for alternative more mechanism-based treatments to
control the extreme symptoms of VVH from endometriosis.
Palmitoylethanolamide (PEA), an endogenous fatty acid amide,
is emerging as an innovative therapeutic approach to chronic
inflammation associated with pain.47 It downmodulates mast
cell (MC) activation and controls glial cell behaviours and
angiogenetic processes alongside inflammatory reactions, thus
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having potential effectiveness in VVH from endometri-
osis.2,10,16,17,19,21,46,49,53,54,56,57,62 Recent experimental studies,
indeed, have highlighted the importance of MC activity in the
development and algogenic capacity of endometriosis.35 Stem cell
factor, the major growth differentiation and chemoattractant factor
for MCs, is elevated in the peritoneal fluid of ENDO patients.52
Degranulating MCs (releasing several mediators, including nerve
growth factor [NGF]) have also been found in deep infiltrating ENDO
lesions, proximal to nerves, suggesting that MCs may contribute to
ENDO pain by a direct effect on nerve structures.3,5,9,39,65,68 Mast
cells contribute to neoangiogenesis, another ENDO feature, which
guarantees oxygen supply to lesions. The expression of vascular
endothelial growth factor (VEGF), the most potent proangiogenic
factor, in fact, is increased in humanENDO samples, and VEGFmay
be released by endometriotic and inflammatory/immune cells,
including MCs.13,20,32,42,43,48,51,55,58,66
Palmitoylethanolamide, exogenously administered, has shown
anti-inflammatory and analgesic effects in experimental models of
chronic inflammation andof acute and chronic neuropathic pain, and
in several human pathological pain conditions,12,24,61 with a higher
efficacy displayed by the oral ultramicronized form in a rat model of
inflammatory pain.36 Analgesic effects of micronized/ultramicronized
PEA for pelvic pain are also suggested by clinical pilot studies.11,31,37
No research has tested the compound in VVH from endometriosis.
Controlled studies in patients would be problematic, due to high
variability of the clinical parameters. Our aim was therefore to assess
the effects of ultramicronized PEA in standardized conditions in the
ENDO1STONE animal model on behavioural indicators of VVH in
parallel with evaluation of ENDO morphological and biochemical
parameters related to MC expression.
2. Materials and methods
2.1. Animals
Female Sprague-Dawley rats (weight: 220-240 g) were used for
the study.
2.2. Experimental protocol
The experiments adhered to the guidelines of the Committee for
Research and Ethical Issues of IASP, and the protocol was
approved by the Ethics Committee for Animal Studies of the
“G. D’Annunzio” University of Chieti (46/2012).
2.2.1. Main experiment: effects of ultramicronized
palmitoylethanolamide on ENDO1STONE
Themain experimentwas conducted in ratswith ENDO1STONE to
assess the effects of ultramicronized PEA vs placebo on pain
behaviour and on morphological and biochemical parameters of
MC activation. The ultramicronization process reduces large drug
crystals down to the submicron range (0.6–6.0 mm ultramicronized
PEA vs 100–700 mm naı¨ve PEA) and also yields a different
crystalline structure increasing energy content; this enhances
diffusion and distribution of the orally administered compound.36
A total of 60 rats were used for this experiment (30 treated with
placebo and 30 with ultramicronized PEA); pain behaviour was
recorded in all of them, while morphological parameters (number of
MCs and their percentage of degranulation, vessel number in cysts)
were assessed in half of the sample (15 placebo and 15
ultramicronized PEA) and biochemical parameters (Western blot
analysis: chymase, VEGF,NGF, Flk-1 in cysts) were assessed in the
remaining half (15 placebo and 15 ultramicronized PEA). Nerve
growth factor also was assessed in the dorsal root ganglia (DRG) in
18 of the rats (9 placebo and 9 ultramicronized PEA) used for the
biochemical parameter evaluation in cysts (see details below).
Sixty rats thus underwent induction of experimental endome-
triosis andwere subsequently randomly assigned to 1 of 2 groups
of 30 rats each, to undergo one of the following treatments:
(1) Ultramicronized palmitoylethanolamide, in the dose of
10 mg·kg21·d21, resuspended in 1.5% carboxycellulose wt/
vol in saline;
(2) Placebo, ie, 1.5% carboxycellulose wt/vol in saline in an
equivalent volume.
The ultramicronized PEA dose used was chosen based on
previous data from the literature about PEA effects on pain
behaviour in other animal models36 and on the results of preliminary
experiments with different doses of ultramicronized PEA in small
groups of ENDO1STONE rats (Table 1). These preliminary
experiments, although not showing a dose–response effect for
ultramicronized PEA, clearly evidenced a marked efficacy of the 10
mg/kg dose, which therefore was selected.
The treatment was administered orally once a day for the whole
experimental period; the first administration was delivered on the
day of endometriosis induction (5 hours after the start of the
intervention, ie, 2 PM), the last on the 25th day post-
endometriosis. The timing of the daily administration (except the
first day) was always 9 AM.
On the 21st day, post-endometriosis, all animals underwent
stone formation in the left ureter (start of intervention soon after
treatment administration). For the subsequent 4 postoperative
days (until the 25th day post-endometriosis, ie, fourth day post-
stone), all rats (30 placebo and 30 ultramicronized PEA) were
video-recorded 24 hours a day to evaluate their spontaneous
behaviour, indicative of both ureteral and uterine pain.
In the evening of the 25th day post-endometriosis (fourth day
post-stone formation), all animals were killed using CO2 and an
autopsy was performed to evaluate the condition of the urinary
tract and the status of the endometrial cysts (to count their
number, and measure their diameter). The endometrial cysts and
Table 1
Preliminary experiment for dose selection.
Parameters Placebo PEA 2.5 PEA 5 PEA 10
Number of ureteral crises (P , 0.03), n 14.67 6 2.75 13.83 6 2.17 13.33 6 2.86 4.67 6 1.52*
Global duration of ureteral crises (P , 0.003), min 115.67 6 16.70 104.17 6 22.17 97.81 6 20.40 14.83 6 4.34**
Mean complexity of ureteral crises (P , 0.04), au 1.56 6 0.05 1.56 6 0.08 1.47 6 0.12 1.22 6 0.09
Global duration of uterine pain (P , 0.04), min 104.98 6 23.28 97.40 6 18.75 88.83 6 14.52 32.76 6 8.66*
Number of cysts (n.s.), n 3.83 6 0.62 3.87 6 0.48 3.62 6 0.32 3.33 6 0.67
Diameter of cysts (P , 0.04), mm 3.68 6 0.46 3.57 6 0.31 3.31 6 0.26 2.43 6 0.21
Ureteral and uterine pain behaviours and cyst parameters in rats with ENDO1STONE treated with different doses of ultramicronized PEA (2.5, 5, or 10 mg·kg21·d21) and placebo, orally, for 25 d, from the day of endometriosis
induction till the fourth day subsequent to stone induction (performed on day 21); mean 6 SEM (n 5 6 rats per group). P values refer to 1-way ANOVA: significant trend for all parameters.
*P , 0.05; **P , 0.01, asterisks refer to comparison of ultramicronized PEA 10 mg·kg21·d21 with placebo (post hoc tests).
ANOVA, analysis of variance; ENDO1STONE, endometriosis plus ureteral calculosis; n.s., nonsignificant; PEA, ultramicronized palmitoylethanolamide.
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spinal cord (T11–L2 segments) were subsequently removed. For
both the placebo and ultramicronized PEA groups, soon after the
explant, the samples were immediately either stored in 4%
formaldehyde or frozen in liquid nitrogen and subsequently stored
at 280˚C. Samples of endometrial cysts were used to perform
morphological analyses (15 rats of the placebo group and 15 of
the ultramicronized PEA group) and biochemical analyses (the
remaining 15 rats of the placebo group and 15 of the ultra-
micronized PEA group). In particular, MCnumber and percentage
of degranulation and vessel number in the cysts were evaluated
as described in the Staining techniques section. The expression
in the tissues of the proangiogenic mediator, VEGF, and its
receptor Flk-1, was evaluated, together with the assessment of
the neurotrophin NGF. Furthermore, expression of the specific
MC marker chymase was evaluated.
2.2.2. Secondary experiment: effects of ultramicronized
palmitoylethanolamide on STONE-only
The secondary experiment was conducted in rats undergoing
formation of artificial ureteral calculosis only, to assess any direct
effect of ultramicronized PEA on ureteral pain behaviour and stone
expulsion in the absence of endometriosis.30 Twenty Sprague-
Dawley rats (220-240g)were randomly assigned to 1 of 2 groupsof
10 animals each, to undergo one of the following treatments:
(1) Ultramicronized palmitoylethanolamide, in the dose of
10 mg·kg21·d21, resuspended in 1.5% carboxycellulose wt/
vol in saline;
(2) Placebo, ie, 1.5% carboxycellulose wt/vol in saline in an
equivalent volume.
The treatment was administered orally once a day for 25 days.
On the 21st day, all rats underwent stone formation in the left
ureter. The timing of the daily administrationwas always 9 AM. From
the 21st till the 25th day after the start of treatment (ie, for 4 days
post-stone implantation), theywere video-recorded 24 hours a day
to evaluate their spontaneous behaviour indicative of ureteral pain.
In the evening of the 25th day, all ratswere killed usingCO2 andan
autopsy was performed to evaluate the condition of the urinary tract.
2.3. Surgical induction of endometriosis
Apreviously establishedmodel of endometriosis that reduces fertility
and produces vaginal hyperalgesia was used.7,50 The animals were
anaesthetized with pentobarbital (50 mg/kg, intraperitoneally [i.p.]),
the uterus was exposed through a midline abdominal incision, and
a 1-cm segment of the right uterine horn was removed. Five pieces
of endometriumwere cut from this segment and were sewn around
small vessels in various structures using nylon suture, ie, 3 pieces on
alternate cascade mesenteric arteries that supply the caudal small
intestine, one on the internal lower abdominal wall, on the right side,
and one on the left ovary.26,44
2.4. Ureteral stone implantation
Under pentobarbital anaesthesia (50 mg/kg, i.p.), the left ureter
was approached by means of laparotomy and a 0.02mL bolus of
dental cement (DuraLay, Dental Mfg. Co) was injected, while still
fluid, into the upper third of the lumen, using a syringe with a 0.4
mm diameter needle according to a technique already described
in detail elsewhere.30
2.5. Quantification of visceral pain behaviours
After surgery, each rat was placed in an individual plexiglass cage
with free access to food and water. As reported above, for 4
postoperative days starting immediately after stone implantation,
all rats underwent 24 hour a day videotape recording with a time-
lapse system, with ultrared lighting for filming during the dark
phase (8 PM to 8 AM). The analysis of the whole period of recording
(performed by observers blinded to the rat’s experimental group)
allowed the evaluation of spontaneous pain behaviours.
Two types of pain behaviours were counted in ENDO1STONE
rats: “ureteral pain crises” and “uterine pain behaviours,” as
characterized in previous studies.26,30,44 A ureteral pain crisis
consists of a sequence of at least 3 pain behaviours (of 6 possible)
within a period of minimum 2-minute duration. The 6 possible
behaviours are “humpbacked” position, licking of the lower
abdomen and/or left flank, contraction of the left oblique
musculature with inward moving of the ipsilateral hindlimb
(“inward”), stretching of the body with raised abdomen
(“stretch-stone”), squashing of the lower abdomen against the
floor (“squash-stone”), and “supine” position with left hindlimb
adducted and compressed against the abdomen. Complexity of
each crisis is estimated using a 4-point arbitrary scale: 3
movements are scored 1, 4 movements are scored 2, 5
movements are scored 3, and, finally, all 6 movements are
scored 4. For each rat, relative to the whole period of recording,
the ureteral crises are characterized in terms of number, global
duration (sum of duration of all crises), and complexity.
Uterine pain behaviours occur between ureteral crises; they are
called uterine because they resemble the behaviours occurring in
a model of experimental uterine inflammation.69 These consist of 4
positions: “lambda” position (the rat suddenly hunches its back
upwards into a sharp angle to form a triangular shape relative to the
floor), “alpha” position (rat with abdomen adherent to the floor and
nose curving towards the tail of the affected side), “stretch-flat”
position, with stretching of the body with abdomen adherent to the
floor, and “squash-pelvic” position (squashing of the lower part of
the abdomen to the floor while in a standing or sitting position). For
each rat, relative to the whole period of recording, the uterine pain
behaviours are characterized in terms of global duration of uterine
positions (sum of duration of all positions).26,30,44
In rats with STONE-only, which present exclusively ureteral
pain behaviour, only this type of behaviour was quantified.
2.6. Evaluation of endometrial cysts and stone expulsion
At autopsy performed on the 25th day post-endometriosis (fourth
day post-stone formation), the following were evaluated in each
rat: number and diameter of endometrial cysts and status of the
urinary tract, ie, stone absent (expelled) or present (retained).
2.7. Staining techniques
The endometrial cysts were collected on the 25th day after the
surgical procedure from 15 rats of the placebo group and 15 of the
ultramicronized PEA group and immediately fixed in 4% neutral
buffered formalin and routinely processed for histology. Serial
sections (7 mm) of paraffin-embedded tissues were cut. For each
cyst, 20 sections were cut and used for the staining procedures. For
histological evaluation of number and degranulation of MCs, the
sections were stained according to the routine procedure with
toluidine blue. For determination of vessel number, the sectionswere
stained with haematoxylin and eosin.15
2.8. Assessment of density of mast cells
For each cyst, 10 sections were deparaffinized in 2 changes of
xylene and hydrated through 2 changes of alcohol, 5 minutes in
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each solution. Then, the sections were kept in water for 5
minutes. The sections were then placed in a coupling jar
containing toluidine blue stain for 30 minutes and then blotted
carefully. They were then placed in absolute alcohol for 1 minute,
cleared in xylene, and mounted on the slide using Entellan. The
granules of MCs were stained purple, and the rest of the section
was stained blue. The MC count was carried out on each slide
using a 103 objective. Density was assessed by counting
the MCs in the total section, divided by the area of tissue. The
percentage of degranulation was obtained by counting the
degranulated MCs at a high magnification (3400), divided by
the total MC number. Quantitative evaluations were performed by
a researcher blinded to the origin of the material.
2.9. Assessment of the number of vessels
For each cyst, 10 sections were deparaffinized and stained
according to the routine procedure with haematoxylin and eosin.
The number of vessels was determined in the total section. The
results were expressed as total vessels per tissue area.
Quantitative evaluations were performed by a researcher blinded
to the experiment.
2.10. Western blot analysis
Western blot analysis was performed on samples of homoge-
nized endometrial cysts (from 15 rats of the placebo group and 15
of the ultramicronized PEA group) and from samples of
homogenized DRG (9 rats of the placebo group and 9 of the
ultramicronized PEA group). Briefly, frozen samples of both
endometrial cysts and DRG, collected on the 25th day post-
endometriosis, were defrozen and then tissue lysed in 250 mL of
ice-cold hypotonic lysis buffer and incubated on ice for an
additional 45 minutes. The total protein extract was obtained by
centrifugation at 14,000 rpm for 10 minutes at 4˚C.
Endometrial cyst samples (50 mg/mL) were subjected to SDS-
polyacrylamide gel electrophoresis, and proteins were trans-
ferred onto nitrocellulose membrane and incubated with one of
the following antibodies: rabbit anti-VEGF (1:1000 vol/vol; Merck
Millipore, Darmstadt, Germany), mouse anti-b-actin (1:1000 vol/
vol; Santa Cruz Biotechnology, Dallas, TX), goat anti–mast cell
chymase (1:1000 vol/vol; Santa Cruz Biotechnology), goat anti-
NGF (1:1000 vol/vol; Novus Biologicals, Cambridge, United
Kingdom), mouse anti-VEGF_r2 (Flk-1) (1:1000 vol/vol; Santa
Cruz Biotechnology). Samples from DRG (50 mg/mL) were
subjected to SDS-polyacrylamide gel electrophoresis and in-
cubated with goat anti-NGF antibody (1:1000 vol/vol; Novus
Biologicals).
Appropriate peroxidase-conjugated secondary antibodies
(1:1000 vol/vol; PerkinElmer, Waltham, MA) were used, and
proteins were visualized using an enhanced chemiluminescence
kit (GE Healthcare, Little Chalfont, Buckinghamshire, United
Kingdom). Protein expression was quantified by densitometric
analysis of the acquired images by ImageQuant 400 (GE
Healthcare) and a computer program (Quantity One, Bio-Rad,
Hercules, CA).
Figure 1.Number (A), global andmean duration (logarithmic scale) (B) andmean complexity (C) of ureteral crises, and global duration of uterine pain (D) in rats with
endometriosis plus ureteral calculosis treated with placebo (n 5 30) or ultramicronized palmitoylethanolamide PEA, (n 5 30); mean 6 SEM. ***P , 0.001:
comparison between placebo and ultramicronized palmitoylethanolamide. A.U., arbitrary units.
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2.11. Statistical analysis
2.11.1. Behavioural and autopsy data
For each rat, the following were calculated: number, global
duration, mean duration, and mean complexity of ureteral
crises and global duration of uterine pain behaviour expressed
over the whole 4-day post-stone formation period; number of
ureteral crises separately for each post-stone day; and number
andmean diameter of endometrial cysts. For each group of rats
(placebo and ultramicronized PEA), mean, SD, and SEM were
calculated for all parameters. For the preliminary experiment,
the comparison between the 4 groups of animals (placebo and
3 doses of ultramicronized PEA) was performed by 1-way
analysis of variance (ANOVA), followed by post hoc tests, for
each parameter. For the main experiment, the trend for
variation of daily ureteral crises in the post-stone period was
calculated using 1-way ANOVA for both placebo and ultra-
micronized PEA groups. For the main and secondary experi-
ments, the comparison between the 2 groups (placebo and
ultramicronized PEA) was performed by Student t test for
unpaired data.
The percentage of stone expulsions was calculated for
each group of rats. The comparison between placebo-treated
and ultramicronized PEA-treated groups was performed using
the x2 test.
For ultramicronized PEA-treated groups of both the main
and secondary experiments, the mean percentage of decrease
in pain behaviour with respect to placebo was calculated
(for all parameters). The comparison between these percen-
tages in the main and secondary experiments was performed
by the x2 test.
The correlation between cyst parameters and pain behaviour
was performed by linear regression analysis.
2.11.2. Morphological and biochemical data
For each group of rats in the main experiment (placebo and
ultramicronized PEA), mean, SD, and SEM were calculated for all
parameters. The statistical comparison between the 2 groups was
performed by 1-way ANOVA followed by Bonferroni test for
multiple comparisons. The correlation of the morphological and
biochemical parameters with pain behaviour was performed by
linear regression analysis.
The level of significance was assessed at P , 0.05.
3. Results
No rat showed any sign of chronic suffering during the whole
experimental period.1 Ultramicronized palmitoylethanolamide rats
but not placebo rats showed a clear docility status; ultramicronized
PEA animals, in contrast to placebo animals, in fact, never showed
aggressive reactions when approached, touched, or handled for
the administration of therapy. Furthermore, abdominal examination
during the intervention for stone formation revealed fewer visceral
conglomeration/adherences in ultramicronized PEA than in
placebo rats.
3.1. Main experiment
3.1.1. Visceral pain behaviour
The videotape analysis allowed for evaluation of pain behaviour,
both urinary and uterine.
3.1.1.1. Ureteral pain behaviour
The ultramicronized PEA group showed significantly lower
number, global duration, mean duration, and mean complexity of
ureteral crises than the placebo group (P , 0.0001) (Fig. 1A–C).
3.1.1.2. Uterine pain behaviour
Ultramicronized palmitoylethanolamide rats showed a signifi-
cantly lower duration of uterine pain behaviour than placebo rats
(P , 0.0001) (Fig. 1D).
3.1.2. Autopsy findings
3.1.2.1. Endometrial cysts
Both placebo and ultramicronized PEA rats developed secretory
cysts in variable number and dimension at the site of the implants.
The 2 groups did not differ in cyst number, while cyst diameter
was significantly smaller in ultramicronized PEA than in placebo
animals (P , 0.03) (Fig. 2A, B).
3.1.2.2. Urinary tract
In the ultramicronized PEA group, a higher percentage of rats
in which the stone was expelled was found compared with
the placebo group and the difference was statistically significant
(P , 0.002) (Fig. 2C).
Figure 2.Number (A) andmean diameter (B) of endometrial cysts and percentage of rats that proved to have expelled their ureteral stone at autopsy (C). *P, 0.05;
**P , 0.01.
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3.1.3. Visceral pain behaviour vs autopsy findings
3.1.3.1. Behaviour vs cyst parameters
In all animals, a significant direct linear correlation was found
between the diameter of the cysts and the global duration of ureteral
pain behaviour (P,0.0001, r50.8739; Y521.392129.511X for
placebo; P , 0.0001, r 5 0.9080; Y 5 27.292 1 7.93X for
ultramicronized PEA).
3.1.3.2. Behaviour vs stone expulsion/retention
All parameters of visceral pain behaviour, calculated separately
for rats that proved to have expelled the stone and rats that had
retained the stone, are displayed in Figure 3A–D, relative to
the whole 4-day post-stone formation period, for both placebo
and ultramicronized PEA groups. The differences between the
expelled stone (ES) and retained stone (RS) animals were not
significant. The daily distribution of the ureteral crises in the ES
and RS animals, reported in Figure 3E, F for placebo and
ultramicronized PEA, was similar and not significantly different.
Also, the time from stone formation to the last uterine pain
behaviour was not significantly different in ES and RS animals for
both placebo and ultramicronized PEA groups (placebo: for ES,
71.06 6 11.53 hours and for RS, 75.88 6 15.47 hours;
ultramicronized PEA: for ES, 57.2 6 17.44 hours and for RS,
66.8 6 17.8 hours).
Figure 3. Spontaneous pain behaviour differentially shown for rats that proved to have expelled their stone at autopsy (n5 4 for the placebo group and n5 17 for
the ultramicronized palmitoylethanolamide [PEA] group) and rats in which the stone was retained in the urinary tract (n5 26 for the placebo group and n5 13 for
the ultramicronized PEA group) (mean 6 SEM). (A) Total number of ureteral crises over the post-stone formation period (from day 0 [stone formation] to day 4
[suppression and autopsy]). (B) Global duration (sum of duration of all crises) and mean duration of ureteral crises over the post-stone formation period. (C) Mean
complexity of ureteral crises over the post-stone formation period. (D) Global duration of uterine pain behaviour over the post-stone formation period. (E and F)
Number of ureteral crises relative to each day of recording in the post-stone formation period in placebo and ultramicronized PEA rats, respectively.
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3.1.4. Morphological and biochemical parameters
3.1.4.1. Mast cells and vessel density in cysts
Histological analysis of ENDO cysts from ultramicronized PEA-
treated animals (Fig. 4A, left panel) showed lower MC density
compared with the placebo group. In parallel, when MC counting
was performed, a significant reduction in their number was
observed in the ultramicronized PEA group compared with
placebo (P , 0.01) (Fig. 4A, right panel). In a similar experiment,
no differences were visible in the percentage of MC degranulation
between the groups (placebo: 57.24 6 2.32; ultramicronized
PEA: 61.87 6 2.054, in mean 6 SD) (data not shown).
Moreover, histology of ENDO cysts from ultramicronized PEA-
treated animals (Fig. 4B, left panel) also showed a reduced
presence of vessels compared with the placebo group; similarly,
when vessel counting was performed, a significant reduction in
the number of vessels at cyst level was found in ultramicronized
PEA-treated rats compared with placebo-treated rats (P, 0.01)
(Fig. 4B, right panel).
3.1.4.2. Chymase, nerve growth factor, vascular endothelial
growth factor, and Flk-1 protein expression in cysts
Ultramicronized palmitoylethanolamide treatment in animals with
ENDO produced a significant reduction of the following protein
levels in cysts: chymase (a marker of MCs) (P , 0.05), NGF (the
proalgogen neurotrophin) (P , 0.05), and VEGF (the main
proangiogenic factor), together with its receptor Flk-1 (P ,
0.01), with respect to placebo (Fig. 5).
3.1.4.3. Nerve growth factor in dorsal root ganglia
Ultramicronized palmitoylethanolamide treatment of ENDO ani-
mals significantly reduced the level of NGF immunoreactive
protein in DRG compared with placebo treatment (P , 0.05)
(Fig. 6).
3.1.5. Visceral pain behaviour vs morphological and
biochemical parameters
A significant direct linear correlation was found between the
global duration of ureteral crises and MC number in cysts,
chymase in cysts, and NGF in cysts and DRG (Table 2).
3.2. Secondary experiment
The results of the behavioural experiment on STONE-only rats are
reported in Figure 7. Ultramicronized palmitoylethanolamide vs
placebo treatment reduced the spontaneous ureteral pain
behaviour; the difference was significant for the number of crises
(P , 0.05). Ultramicronized palmitoylethanolamide also in-
creased the percentage of stone expulsions with respect to
placebo, although the difference was not significant, probably
because of the limited sample size.
3.3. Main experiment vs secondary experiment for ureteral
pain behaviour and stone expulsion
The 10 mg/kg dose of ultramicronized PEA in ENDO1STONE
produced a mean reduction of ureteral pain behaviour of 71% for
number, 86% for global duration, and 20% for complexity of crises.
The same dose in STONE-only rats reduced ureteral pain
behaviour by 38% for number, 48% for global duration, and 6%
for complexity.
The reduction of ureteral pain behaviour with ultramicronized
PEA vs placebo was significantly more pronounced in ENDO1
STONE than in STONE-only rats (P , 0.0001 for number and
Figure 4. Histological analysis of endometriosis cysts in placebo-treated and ultramicronized palmitoylethanolamide (PEA)–treated rats. Panel A shows toluidine
blue staining for mast cells (left) and mast cell number per area (in square millimeters) (right). Panel B shows haematoxylin and eosin staining for morphology (left)
and vessel number per area (in square millimeters) (right); mean6 SEM (n5 15 rats for placebo and n5 15 rats for ultramicronized PEA). **P, 0.01: comparison
between placebo and ultramicronized PEA-treated animals.
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global duration; P , 0.007 for complexity; x2 test between
percentages of reduction in the 2 groups).
The percentage of stone expulsions was slightly less pro-
nounced in ENDO1STONE (57%) than in STONE-only rats
treated with ultramicronized PEA (60%) (17/30 vs 6/10), but the
difference was not statistically significant (x2 test).
4. Discussion
Pain is themost frequent reason for medical consultation, and the
extreme pain of VVH generated by endometriosis represents
a most challenging problem for the clinician.27 In this study, we
evaluated a new possibility for VVH therapy with ultramicronized
PEA using a standardized rat model of VVH from endometriosis
plus ureteral calculosis, which closely mimics the clinical
condition in comorbid women. Our results showed that
prolonged oral treatment with ultramicronized PEA during cyst
formation (starting 3 weeks before stone induction), when
compared with placebo, significantly and notably reduced the
behavioural indices of both uterine and ureteral pain, in parallel
with a reduction of cyst diameter. This same treatment also
increased the percentage of stone expulsions. The positive
effects of this treatment occurred in the absence of any significant
adverse event, with the animals showing no signs of chronic
suffering.
In this study, we used a 10 mg/kg ultramicronized PEA dose,
based on previous investigation in other animal models36 and
on our preliminary experiments with different doses of the
compound, which showed a clear effect of the 10mg/kg regimen
in counteracting the ureteral and uterine pain behaviours. Under
our experimental conditions, a clear dose-related effect was not
observed, although a PEA dose–response effect has been
reported previously in different models of inflammation and of
acute and chronic/neuropathic pain (see Refs. 46,49). It is,
however, not totally unexpected that the effective concentration
range of PEA should vary as a function of the experimental model,
the mode of administration used, and the parameters investi-
gated. Identifying the precise range in which PEA is pharmaco-
logically active is complicated by its lipophilic nature; furthermore,
comparisons between studies are difficult because of the use of
different vehicles for suspension or solubilization. Our study is the
first to evaluate the effects of ultramicronized PEA in a model of
VVH, which likely involves altered function of converging sensory
projections and central sensitization sustained by dysregulation of
immune cells activity such as MCs and microglia. In this complex
setting,multiplemechanisms are likely to be implicated in both pain
pathogenesis and PEA pharmacological actions. In our study, we
directed our attention to the involvement of MCs, though future
investigation will be needed to evaluate other possible mecha-
nisms. The involvement of MCs in ENDO is well known, and they
are a recognized target for PEA action.3,5,39,52,65 Histological
analysis showed oral ultramicronized PEA treatment to significantly
reduce the number of MCs in ENDO cysts. This effect was
confirmed by the biochemical analysis of chymase, a serine
protease selectively stored in MC granules. This result is in line with
Figure 6. Western blot analysis for nerve growth factor (NGF) in dorsal root
ganglia of rats with endometriosis from placebo-treated and ultramicronized
palmitoylethanolamide (PEA)–treated rats. The figure shows a representative
Western blot analysis of proteins (upper) and densitometric analysis (lower) of
corresponding bands. b-actin expression is shown as control; mean 6 SEM
(n 5 9 rats for placebo and n 5 9 rats for ultramicronized PEA). *P , 0.05:
comparison between placebo and ultramicronized PEA-treated animals.
Figure 5. Western blot analysis for chymase (A), vascular endothelial growth
factor (VEGF) (B), nerve growth factor (NGF) (C), and Flk-1 (D) of endometriosis
cysts from placebo-treated and ultramicronized palmitoylethanolamide (PEA)–
treated rats. The figure shows a representative Western blot analysis of
proteins (upper) and densitometric analysis (lower) of corresponding bands.
b-actin expression is shown as control; mean6 SEM (n5 15 rats for placebo
and n 5 15 rats for ultramicronized PEA). *P, 0.05, **P , 0.01: comparison
between placebo and ultramicronized PEA-treated animals.
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previously reported analgesic effects of PEA, since different studies
have demonstrated that PEA control of MC behaviour is reflected
in a reduced pain perception.8,18 Mast cell granules contain, in
fact, proalgogenic mediators, primarily NGF.40,63 Indeed after
ultramicronized PEA oral treatment, we found, in ENDO cysts,
a significant reduction of NGF levels in parallel with the reduction of
MC number.
As previously reported,MCs also play a pivotal role in the control
of angiogenesis and neurogenesis, key features of ENDO.4,32,55
For this reason, we first studied the role of ultramicronized PEA in
angiogenesis during ENDO. Here, for the first time, we demon-
strate a strong antiangiogenic role of ultramicronized PEA in this
condition, since histological analysis of ENDO cysts from animals
receiving the compound revealed a significant reduction of blood
vessels compared with placebo-treated animals. The antiangio-
genic effect of ultramicronized palmitoylethanolamide was corrob-
orated by Western blot analysis of VEGF, the main proangiogenic
mediator, and its receptor Flk-141 in the cysts. Our data
demonstrated that ultramicronized PEA oral treatment significantly
inhibits VEGF pathways (expression levels of both VEGF and its
receptor) in ENDO cysts. It is conceivable that VEGF down-
regulation is due to MC modulation exerted by the compound
because VEGF is released mainly by MCs during chronic
inflammation.25 The reduced angiogenesis associated with ultra-
micronized PEA treatmentmay justify, at least in part, the reduction
in cyst diameter reported here. In fact, new vessel formation is
required for supplying oxygen and nutrients to ENDO cysts,
facilitating their development and implantation.
Figure 7. Number, global and mean duration (logarithmic scale) and mean complexity of ureteral crises and percentage of stone expulsion in rats with ureteral
calculosis–only treated with placebo or ultramicronized palmitoylethanolamide (PEA) (10 rats per group). *P , 0.05: comparison between placebo and
ultramicronized palmitoylethanolamide.
Table 2
Correlation between morphological and biochemical parameters and spontaneous pain behaviour.
Group of rats Ureteral behaviour
(N 5 15 per group), min
MC number in cysts
vs ureteral behaviour
(N 5 15 per group)
Chymase in cysts
vs ureteral behaviour
(N 5 15 per group)
NGF in cysts vs
ureteral behaviour
(N 5 15 per group)
NGF in DRG vs
ureteral behaviour
(N 5 9 per group)
Morph
Placebo 103.07 6 17.17 Y 5 22.003 1 2.258X;
r 5 0.8404; P , 0.0001
___ ___ ___
PEA 13.87 6 2.55 Y 5 21.567 1 0.5033X;
r 5 0.8148; P , 0.0003
___ ___ ___
WB
Placebo 104.27 6 11 ___ Y 5 7.721 1 81.772X;
r 5 0.8741; P , 0.0002
Y 5 242.955 1 137.25X;
r 5 0.7935; P , 0.0005
Y 5 27.456 1 82.854X;
r 5 0.7617; P , 0.02
PEA 14.8 6 2.03 ___ Y 5 24.546 1 23.402X;
r 5 0.8283; P , 0.0002
Y 5 213.465 1 32.415X;
r 5 0.7828; P , 0.0007
Y 5 22.497 1 17.32X;
r 5 0.6689; P , 0.05
Morph: rats in which morphological parameters were evaluated (n 5 15 placebo, n 5 15 ultramicronized PEA); WB: rats in which Western blot parameters were evaluated (n5 15 placebo, n5 15 ultramicronized PEA);
ureteral behaviour: global duration of ureteral crises on the post-stone days.
DRG, dorsal root ganglia; MC, mast cell; NGF, nerve growth factor; PEA, ultramicronized palmitoylethanolamide.
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Second, biochemical analysis of DRG showed that oral
ultramicronized PEA treatment also reduces NGF protein
expression at this level. The latter data strongly support the
notion that the antialgogenic effect of ultramicronized PEA may
be exerted by its control of the neurotrophin NGF, one of themain
mediators activating the algogenic input from the ENDO lesions
towards the central nervous system.59 With this respect, the
direct linear correlation found between NGF in DRG and ureteral
pain behaviour, found in our study, is of particular relevance.
However, other mechanisms beyond the antialgogenic effect
shown by ultramicronized PEA in our model cannot be excluded,
since it already has been demonstrated that anti-inflammatory
and analgesic effects of the compound are mediated through
activation of the peroxisome proliferator–activated receptor
alpha14 and through reduction of the nuclear factor-kappa B
activation in experimental models of hyperalgesia.45
Our results also showed a significant direct correlation
between the ureteral pain behaviour and the number of MCs in
cysts, chymase, and NGF expression at their level, in addition to
the above-mentioned NGF expression in DRG. In view of these
findings, our data on reduced pain behaviour can largely be
attributed to the reduction, due to ultramicronized PEA, of the
amount of algogenic mediators produced by MCs during ENDO
and the consequent degree of central sensitization. The fact that
oral ultramicronized PEA treatment also produced an enhanced
percentage of stone expulsions with respect to placebo
treatment suggests, however, that an action of the compound
on ureteral activity cannot be excluded. We therefore also
performed a separate analysis, in our ENDO1STONE sample,
of the pain behaviour of rats that proved to have eliminated the
stone vs those that had retained it. Although the former presented
a slightly lesser ureteral behaviour than the latter, the difference
between the 2 groups was not significant. There also was no
significant differential distribution of the ureteral pain behaviour
over the different post-stone implantation days in the 2 groups,
suggesting that the event of stone expulsion, occurred during the
recording period in some rats, had not produced dramatic effects
on the subsequent evolution of the behaviour from the ureter.
Regarding the uterine behaviour, this appeared instead slightly
increased in the stone-expelled group as compared with the
stone-retained group, although here again the difference was not
significant. To further address the important point of the possible
influence of stone expulsion on the reduced pain behaviour
produced by ultramicronized PEA, we also tested the effects of its
administration in rats with ureteral calculosis without associated
endometriosis, using the same dose and duration of treatment as
for rats with ENDO1STONE. A mild reduction of ureteral pain
behaviour by ultramicronized PEA was observed in the STONE-
only model, but the extent of this reduction was significantly less
pronounced than in ENDO1STONE, despite the fact that the
percentage of stone elimination was even slightly more pro-
nounced. This outcome on one hand confirms that the promotion
of stone expulsion by ultramicronized PEA plays a role in its
antalgic effects, although the mechanism by which this occurs
will need to be further investigated, and on the other hand,
however, it points out that a major contribution to VVH reduction
by ultramicronized PEA is likely to be related to an effect at the
ENDO level, also considering that the compound significantly
decreased uterine pain behaviour, which only appears when
utereral calculosis is combinedwith endometriosis. Regardless of
possible mechanisms, the present data are of importance in view
of the clinical application of ultramicronized PEA, even though the
compound is not yet available in all countries. These data provide
experimental support to the results of a recent clinical study
showing that PEA (comicronized with transpolydatin, 400 1 40
mg 3 2/d for 3 months) reduced chronic pelvic pain and
dysmenorrhoea fromendometriosis.31While our findings suggest
that orally administered ultramicronized PEA in patients could be
particularly useful, alone or in combination with classic anti-
inflammatory/analgesic treatments, for managing the extreme
condition of VVH occurring when endometriosis is comorbid with
urinary pain from calculosis, clinical studies will be needed for
confirmation.
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